Progyny Yönetim
Yönetim kriter kontrolleri 4/4
Progyny CEO'su Pete Anevski, Jan2022 tarihinde atandı, in görev süresi 2.83 yıldır. in toplam yıllık tazminatı $ 1.09M olup, şirket hissesi ve opsiyonları dahil olmak üzere 45.7% maaş ve 54.3% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.17% ine doğrudan sahiptir ve bu hisseler $ 2.56M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.8 yıl ve 7.7 yıldır.
Anahtar bilgiler
Pete Anevski
İcra Kurulu Başkanı
US$1.1m
Toplam tazminat
| CEO maaş yüzdesi | 45.7% |
| CEO görev süresi | 2.8yrs |
| CEO sahipliği | 0.2% |
| Yönetim ortalama görev süresi | 2.8yrs |
| Yönetim Kurulu ortalama görev süresi | 7.7yrs |
Son yönetim güncellemeleri
Recent updates
Here's What's Concerning About Progyny's (NASDAQ:PGNY) Returns On Capital
Oct 21
Progyny: Poor Year Raises Concerns For Future (Downgrade)
Oct 15Progyny, Inc.'s (NASDAQ:PGNY) Stock Retreats 28% But Earnings Haven't Escaped The Attention Of Investors
Sep 29Progyny: Downgrading As Uncertainties Increase
Aug 15Progyny, Inc. (NASDAQ:PGNY) Stocks Pounded By 25% But Not Lagging Market On Growth Or Pricing
Aug 11At US$27.79, Is Progyny, Inc. (NASDAQ:PGNY) Worth Looking At Closely?
Jul 20Progyny: Recent Stock Decline Provides Buying Opportunity
Jul 12Progyny's (NASDAQ:PGNY) Returns Have Hit A Wall
Jun 23Progyny: At This Price, Secular Tailwinds Are Too Compelling To Ignore
Jun 10Progyny: No Change To Long-Term Outlook
Jun 04Why We're Not Concerned About Progyny, Inc.'s (NASDAQ:PGNY) Share Price
Apr 29Is Now An Opportune Moment To Examine Progyny, Inc. (NASDAQ:PGNY)?
Apr 03Progyny: Long-Term Outlook Remains Positive, Reiterate Buy
Mar 15Progyny: Long-Term Thesis Still Intact
Mar 09Progyny's (NASDAQ:PGNY) Returns On Capital Are Heading Higher
Mar 01Progyny, Inc.'s (NASDAQ:PGNY) P/E Still Appears To Be Reasonable
Jan 07Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?
Dec 11Returns Are Gaining Momentum At Progyny (NASDAQ:PGNY)
Nov 08Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?
Aug 24There's Been No Shortage Of Growth Recently For Progyny's (NASDAQ:PGNY) Returns On Capital
Aug 06Progyny (NASDAQ:PGNY) Is Looking To Continue Growing Its Returns On Capital
May 06When Should You Buy Progyny, Inc. (NASDAQ:PGNY)?
Jan 25Progyny (NASDAQ:PGNY) Shareholders Will Want The ROCE Trajectory To Continue
Dec 12Is It Time To Consider Buying Progyny, Inc. (NASDAQ:PGNY)?
Oct 18CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$63m |
| Mar 31 2024 | n/a | n/a | US$61m |
| Dec 31 2023 | US$1m | US$500k | US$62m |
| Sep 30 2023 | n/a | n/a | US$52m |
| Jun 30 2023 | n/a | n/a | US$49m |
| Mar 31 2023 | n/a | n/a | US$43m |
| Dec 31 2022 | US$69m | US$500k | US$30m |
| Sep 30 2022 | n/a | n/a | US$42m |
| Jun 30 2022 | n/a | n/a | US$46m |
| Mar 31 2022 | n/a | n/a | US$56m |
| Dec 31 2021 | US$786k | US$425k | US$66m |
| Sep 30 2021 | n/a | n/a | US$90m |
| Jun 30 2021 | n/a | n/a | US$78m |
| Mar 31 2021 | n/a | n/a | US$58m |
| Dec 31 2020 | US$910k | US$425k | US$46m |
| Sep 30 2020 | n/a | n/a | US$3m |
| Jun 30 2020 | n/a | n/a | -US$10m |
| Mar 31 2020 | n/a | n/a | -US$5m |
| Dec 31 2019 | US$5m | US$375k | -US$9m |
| Sep 30 2019 | n/a | n/a | -US$6m |
| Jun 30 2019 | n/a | n/a | US$1m |
| Mar 31 2019 | n/a | n/a | -US$4m |
| Dec 31 2018 | US$682k | US$325k | -US$6m |
Tazminat ve Piyasa: Pete 'nin toplam tazminatı ($USD 1.09M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 5.27M ).
Tazminat ve Kazançlar: Pete 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Pete Anevski (57 yo)
2.8yrs
Görev süresi
US$1,093,512
Tazminat
Mr. Peter Anevski, also known as Pete, has been Chief Executive Officer and Director of Progyny, Inc. since January 2022 and had been its President since June 2019 until December 31, 2021 and was its Chief...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Executive Chairman | 7.7yrs | US$513.57k | 0.058% $ 864.0k | |
| CEO & Director | 2.8yrs | US$1.09m | 0.17% $ 2.6m | |
| President | 2.8yrs | US$1.49m | 0.073% $ 1.1m | |
| Chief Financial Officer | 4.2yrs | US$1.40m | 0.049% $ 738.0k | |
| Executive VP | 2yrs | US$546.22k | 0.018% $ 276.2k | |
| Chief Technology Officer | less than a year | Veri yok | Veri yok | |
| Vice President of Investor Relations | no data | Veri yok | Veri yok | |
| Chief Marketing Officer | no data | Veri yok | Veri yok | |
| Chief Human Resources Officer | no data | Veri yok | Veri yok | |
| Chief Business Development Officer | 2.8yrs | Veri yok | Veri yok | |
| Member of the Medical Advisory Board & Chief Medical Officer | 1.6yrs | Veri yok | Veri yok | |
| Senior Vice President of Employer Market Strategy | 2.5yrs | Veri yok | Veri yok |
2.8yrs
Ortalama Görev Süresi
57yo
Ortalama Yaş
Deneyimli Yönetim: PGNY 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.8 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Executive Chairman | 7.7yrs | US$513.57k | 0.058% $ 864.0k | |
| CEO & Director | 2.8yrs | US$1.09m | 0.17% $ 2.6m | |
| Member of the Medical Advisory Board & Chief Medical Officer | no data | Veri yok | Veri yok | |
| Independent Director | 7.9yrs | US$567.30k | 0.45% $ 6.8m | |
| Independent Director | 9.7yrs | US$583.35k | 0.013% $ 201.5k | |
| Lead Independent Director | 14.5yrs | US$653.39k | 0.29% $ 4.3m | |
| Independent Director | 5.1yrs | US$518.30k | 0.0069% $ 103.0k | |
| Independent Director | 5.1yrs | US$606.88k | 0.013% $ 201.5k | |
| Member of the Medical Advisory Board | no data | Veri yok | Veri yok | |
| Member of Medical Advisory Board | no data | Veri yok | Veri yok | |
| Member of Medical Advisory Board | no data | Veri yok | Veri yok | |
| Member of Medical Advisory Board | no data | Veri yok | Veri yok |
7.7yrs
Ortalama Görev Süresi
65yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: PGNY 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.7 yıldır).